The Company has four product candidates in development that address viral infections that have limited therapeutic options.
We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 & 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial.
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.
Biota Pharmaceuticals Office Locations
Biota Pharmaceuticals Financials and Metrics
Biota Pharmaceuticals Financials
| USD | |
|---|---|
Revenue (Q3, 2017) | 4.9 m |
Net income (Q3, 2017) | (4.4 m) |
EBIT (Q3, 2017) | (3.8 m) |
Cash (31-Mar-2017) | 11.8 m |
- Source: SEC Filings
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Revenue | 68.7 m | 24.6 m | 9.3 m |
Revenue growth, % | (64%) | (62%) | |
Cost of goods sold | 51.1 m | 3.6 m | |
Gross profit | 17.6 m | 21 m |
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 12.3 m | 18.5 m | 29.5 m | 700 k | 13.9 m | 5.9 m | 1.7 m | 1.7 m | 5.3 m | 100 k | 3.8 m | 4.9 m |
Cost of goods sold | 10.7 m | 11.4 m | 19.3 m | 1.7 m | 1.6 m | 300 k | ||||||
Gross profit | 1.6 m | 7.1 m | 10.2 m | (1 m) | 12.3 m | 5.6 m | ||||||
Gross profit Margin, % | 13% | 38% | 35% | (143%) | 88% | 95% |
- Source: SEC Filings
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Cash | 81.7 m | 44.7 m | 49.7 m |
Current Assets | 101.1 m | 70.8 m | 72.4 m |
PP&E | 2 m | 200 k | 300 k |
Total Assets | 114 m | 79.4 m | 72.7 m |
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 60.8 m | 51.4 m | 80.1 m | 57.7 m | 63.7 m | 61.5 m | 45.3 m | 39 m | 30.6 m | 45.9 m | 38.1 m | 11.8 m |
Accounts Receivable | 12.9 m | 26.9 m | 36.5 m | 10.1 m | 3.2 m | |||||||
Current Assets | 75 m | 79.3 m | 117.5 m | 76.1 m | 86.2 m | 87.4 m | 61.2 m | 58.6 m | 60.5 m | 62.8 m | 56.2 m | 46.4 m |
PP&E | 3.5 m | 3.1 m | 2.8 m | 1.6 m | 1.1 m | 300 k | 200 k | 400 k | 400 k | 300 k | 300 k | 300 k |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | (11 m) | (19.1 m) | (25.4 m) |
Depreciation and Amortization | 2.4 m | 1.1 m | 100 k |
Cash From Operating Activities | (3.3 m) | (9.6 m) | (14.1 m) |
Purchases of PP&E | (100 k) | (100 k) | (200 k) |
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (3.9 m) | (100 k) | 3.2 m | (6.9 m) | 6.5 m | 1.2 m | (6.6 m) | (6.5 m) | (5.2 m) | (10 m) | (9.1 m) | (4.4 m) |
Accounts Payable | 1.4 m | 1.7 m | 1 m | (2.2 m) | 1.3 m | 3.7 m | 1.6 m | 3.4 m | 1.8 m | |||
Cash From Operating Activities | 900 k | |||||||||||
Cash From Investing Activities | (200 k) |
| USD | Y, 2017 |
|---|---|
Financial Leverage | 1.9 x |
Biota Pharmaceuticals Operating Metrics
| FY, 2016 | |
|---|---|
Marketed Vaccines | 2 |
Phase II Trials Products | 4 |
